Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways

View original at finance.yahoo.com
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways MEDVI Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists Compounded Options Alongside New FDA-Approved Oral Pathway Los Angel…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Payment does not guarantee the writing or dispensing of a prescription

    80% confidence

  • OASIS 4 trial showed approximately 13-14% average weight loss over 64 weeks with oral Wegovy, with up to 16.6% among adherent participants

    80% confidence

  • Limited-time savings offer for oral Wegovy starting dose at approximately $149 per month

    80% confidence

  • MEDVi-affiliated medical professional entities are not contracted healthcare providers with any health insurance plans

    80% confidence

  • Novo Nordisk plans a full U.S. launch of oral Wegovy in early January 2026

    80% confidence

  • The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed

    80% confidence

  • STEP 1 trial demonstrated 14.9% average body weight loss over 68 weeks with Wegovy injection

    80% confidence

  • FDA received reports of adverse events including hospitalizations that may be related to dosing errors with compounded semaglutide products

    80% confidence

  • FDA is not aware of a basis for compounding using salt forms such as semaglutide sodium or semaglutide acetate

    80% confidence

  • Limited-time cash-pay savings offer for Wegovy injection at $199 for initial doses, then $349 thereafter

    80% confidence

  • MEDVi does not provide any Healthcare Services through the Platform and is not licensed to practice medicine

    80% confidence

  • Compounded semaglutide in multi-dose vials can create dosing confusion, especially when instructions use 'units' rather than mg/mL measurements, leading to overdoses in some reported cases

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways — Source | Via News | ViaNews EU